Clinical trial · Interventional
RGD PET/MRI in Sporadic Vestibular Schwannoma
Kan tumorvækst Forudsiges Ved RGD-PET/MR af Vestibularis Schwannomer?
NCT03393689CI-TRIAL-00031133unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of angiogenesis PET/MR with the radioligand 68Ga-NODAGA- E\[c(RGDyK)\]2 in patients with sporadic Vestibuarl Schwannomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acoustic Neuroma | Vestibular Schwannoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| One injection of 68Ga-NODAGA-E[c(RGDyK)]2 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Angiogenesis PET/MR
- description
- One injection of the radioligand 68Ga-NODAGA-E\[c(RGDyK)\]2 followed by PET/MR
- interventionNames
- Drug: One injection of 68Ga-NODAGA-E[c(RGDyK)]2
Primary outcomes (1)
- measure
- Angiogenesis PET/MR imaging of patients with sporadic Vestibular Schwannomas
- timeFrame
- 1 hour
- description
- The radioligand 68Ga-NODAGA-E\[c(RGDyK)\]2 can be used as a prognostic marker for growth rate in patients with sporadic vestibular schwannomas.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Patients \> 18 years with MRI verified sporadic vestibular schwannomas * Patients \> 18 år whom max has been in watchful waiting regime in 12 months and/or max. received 1 follow-up MRI scan. * Must be able to read and understand the patient information in Danish and to give informed consent Exclusion Criteria: * Pregnancy * Breast-feeding * Weight more than the maximum weight limit for the PET/MR bed of the scanner (140 kg) * History of allergic reaction attributable to compounds of similar chemical or biologic composition to 68Ga-NODAGA-E\[c(RGDyK)\]2 * Recent systemic treatment with steroids * Hormone treatment incl. birth control pills. * Claustrofobia * Non-MRI compatible implants.
References
Publications (1)
- DERIVEDSass HCR, Jensen RG, Johannesen HH, Lofgren JO, Loft A, Andersen TL, Hansen AE, Caye-Thomasen P, Kjaer A. Angiogenesis PET/MRI predicts initial growth of sporadic vestibular schwannomas: a prospective study with follow-up in 29 patients using [68Ga]Ga-NODAGA-E[c(RGDyK)]2. EJNMMI Res. 2026 Jan 13;16(1):27. doi: 10.1186/s13550-025-01362-z. PMID 41530428